Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYT1 | Q01538 | 3/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | WEE1 | P30291 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.34 |
| ▸ | GRM5 | P41594 | 4/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24251587 | 0.83 | HPGD (0.44) | HCRTR1HCRTR2 | |
| SCHEMBL24251538 | 0.82 | SPR (0.42) | P2RX7GRM5HCRTR1HCRTR2 | |
| SCHEMBL24251459 | 0.81 | SPR (0.42) | MYT1CDK1ELANEP2RX7GRM5 | |
| SCHEMBL24251483 | 0.81 | P2RX7 (0.53) | P2RX7 | |
| SCHEMBL24251549 | 0.80 | SPR (0.36) | HCRTR1HCRTR2 | |
| SCHEMBL24251391 | 0.80 | CYP3A4 (0.37) | GABRA5HCRTR1HCRTR2 | |
| SCHEMBL24251406 | 0.78 | SPR (0.41) | P2RX7GRM5HCRTR1HCRTR2 | |
| SCHEMBL24251498 | 0.78 | SPR (0.41) | — | |
| SCHEMBL24251385 | 0.78 | SPR (0.40) | DPP4HCRTR1HCRTR2 | |
| SCHEMBL23355438 | 0.77 | PDE4B (0.35) | ELANENOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220048903-A1 | Anthelminthic Heterocyclic Compounds | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048903-A1 | Anthelminthic Heterocyclic Compounds | SDHA, PAH, PIGS | MYT1 1382/4885DPP4 3480/4885CDK1 1186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.